Examining PD-L1 and TMB as Biomarkers of Immunotherapy Response in NSCLC
Published: Thursday, Oct 17, 2019
James G. Herman, MD
Ongoing research is examining how the biomarkers PD-L1 and tumor mutational burden (TMB) can be used in a complementary fashion to predict which patients with advanced non–small cell lung cancer (NSCLC) will benefit most from immunotherapy, said James G. Herman, MD.
... to read the full story